A novel rapamycin cream formulation improves facial angiofibromas associated with tuberous sclerosis complex: a double-blind randomized placebo-controlled trial
British Journal of Dermatology · 2023
DOI: 10.1093/bjd/ljad243 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Phillip Aitken und 20 weiteren Autor:innen. Beteiligte Einrichtung: AFT Pharmaceuticals Ltd, Auckland, New Zealand. Hauptthemen laut MEDLINE: Angiofibroma, Tuberous Sclerosis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dermatology Specialties Limited Partnership (DSLP).
Abstract (Originalsprache)
Background
Facial angiofibromas (FAs) are a major feature of tuberous sclerosis complex (TSC). Topical rapamycin can successfully treat FAs. A new stabilized cream formulation that protects rapamycin from oxidation has been developed in 0.5% and 1% concentrations.
Objectives
To assess the efficacy and safety of a novel, stabilized topical rapamycin cream formulation.
Methods
This multicentre double-blind randomized placebo-controlled dose–response phase II/III study with a parallel design included participants aged 6–65 years with FAs of mild or moderate severity according to the Investigator’s Global Assessment (IGA) scale. Participants were randomized to one of three treatment arms: topical rapamycin 0.5%, topical rapamycin 1% or placebo. Treatment was applied once daily for 26 weeks. Safety and efficacy measures were assessed at days 14, 56, 98, 140 and 182. The primary endpoint was the percentage of participants achieving IGA scores of ‘clear’ or ‘almost clear’ after 26 weeks of treatment. Secondary measures included Facial Angiofibroma Severity Index (FASI) and participant- and clinician-reported percentage-based improvement. Safety measures included the incidence of treatment-emergent adverse events and blood rapamycin concentration changes over time.
Results
Participants (n = 107) were randomized to receive either rapamycin 1% (n = 33), rapamycin 0.5% (n = 36) or placebo (n = 38). All treated participants were included in the final analysis. The percentage of participants with a two-grade IGA improvement was greater in the rapamycin 0.5% treatment group (11%) and rapamycin 1% group (9%) than in the placebo group (5%). However, this was not statistically significant [rapamycin 0.5%: odds ratio (OR) 1.71, 95% confidence interval (CI) 0.36–8.18 (P = 0.50); rapamycin 1%: OR 1.68, 95% CI 0.33–8.40 (P = 0.53)]. There was a statistically significant difference in the proportion of participants treated with rapamycin cream that achieved at least a one-grade improvement in IGA [rapamycin 0.5%: 56% (OR 4.73, 95% CI 1.59–14.10; P = 0.005); rapamycin 1%: 61% (OR 5.14, 95% CI 1.70–15.57; P = 0.004); placebo: 24%]. Skin adverse reactions were more common in patients following rapamycin application (64%) vs. placebo (29%).
Conclusions
Both rapamycin cream formulations (0.5% and 1%) were well tolerated, and either strength could lead to clinical benefit in the treatment of FA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- AFT Pharmaceuticals Ltd, Auckland, New Zealand.
- Dermatology Department, Christchurch Hospital, Christchurch, New Zealand.
- Bethesda Children's Hospital, Budapest, Hungary.
- Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
- Dermatology Department, Clínica Universidad de Navarra, Madrid, Spain.
- University of California San Diego Health Sciences, Department of Neurosciences, San Diego, CA, USA.
ORCID-Profile: Phillip Aitken, Ioana Stanescu, Laura Boddington, Yi-Hua Liao, Marta Ivars, Ester Moreno-Artero, Jasna Jancic, Milos Nikolic, Harper N Price, Kinga Hadzsiev
Förderung
- Dermatology Specialties Limited Partnership (DSLP)
Zitieren
APA
Aitken, P., Stanescu, I., Boddington, L., Mahon, C., Fogarasi, A., Liao, Y. H., Ivars, M., Moreno-Artero, E., Trauner, D., DeRoos, S. T., Jancic, J., Nikolic, M., Balážová, P., Price, H. N., Hadzsiev, K., Riney, K., Stapleton, S., Tollefson, M. M., Bauer, D., …, & Atkinson, H. (2023). A novel rapamycin cream formulation improves facial angiofibromas associated with tuberous sclerosis complex: a double-blind randomized placebo-controlled trial. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad243
Vancouver
Aitken P, Stanescu I, Boddington L, Mahon C, Fogarasi A, Liao YH, et al. A novel rapamycin cream formulation improves facial angiofibromas associated with tuberous sclerosis complex: a double-blind randomized placebo-controlled trial. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad243
BibTeX
@article{Aitken2023,
author = {Aitken, Phillip and Stanescu, Ioana and Boddington, Laura and Mahon, Caroline and Fogarasi, Andras and Liao, Yi-Hua and Ivars, Marta and Moreno-Artero, Ester and Trauner, Doris and DeRoos, Steven T and Jancic, Jasna and Nikolic, Milos and Balážová, Patrícia and Price, Harper N and Hadzsiev, Kinga and Riney, Kate and Stapleton, Stacie and Tollefson, Megha M and Bauer, Derek and Pinková, Blanka and Atkinson, Hartley},
title = {A novel rapamycin cream formulation improves facial angiofibromas associated with tuberous sclerosis complex: a double-blind randomized placebo-controlled trial},
journal = {British Journal of Dermatology},
year = {2023},
doi = {10.1093/bjd/ljad243}
}
EUVIMED